LEXINGTON, Mass. & SAN FRANCISCO–(HSMN NewsFeed)–Antigenics Inc. (NASDAQ:AGEN ) today announced that the Brain Tumor Research Center at the University of California, San Francisco, has begun enrolling patients into a Phase TWO clinical trial of Oncophage (…
Biopharmaceuticals, Oncology
Antigenics , Oncophage, vitespen, glioma

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Patients Begin Enrolling into Investigator-Sponsored Phase 2 Trial of Antigenics’ Oncophage(R) Cancer Vaccine in Newly Diagnosed Glioma”
Leave a Comment